The Food and Drug Administration has given clearance to the first continuous glucose monitoring system with a fully implantable sensor that can be used by adult users with diabetes to regularly measure their blood sugar levels for as long as 90 days.
The Eversense Continuous Glucose Monitoring (CGM) system, manufactured by Senseonics Holdings, leverages a small sensor that is implanted just under the skin by a physician during an outpatient procedure. The sensor takes blood sugar measurements every five minutes and sends information via Bluetooth to a mobile device running an app, which lets users know if the glucose levels are too high or too low.
